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Abstract 
Aim 
To test if spironolactone or dietary nitrate from beetroot juice could reduce arterial 
stiffness as aortic pulse wave velocity (PWVart), a potential treatment target, 
independently of blood pressure.  
Methods 
Daily spironolactone (≤50mg) versus doxazosin (control ≤16mg) and 70mL beetroot 
juice (‘Beet-It’ ≤11mmol nitrate) versus nitrate-depleted juice (placebo; 0mmol nitrate) 
were tested in people at risk or with type-2 diabetes using a double-blind, 6-month 
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factorial trial. Vascular indices (baseline, 12, 24 weeks) were cardiac-ankle vascular 
index (‘CAVI’), a nominally pressure-independent stiffness measure (primary outcome), 
pulse wave velocity (PWVart) secondary, central systolic pressure and augmentation. 
Analysis was intention-to-treat, adjusted for systolic pressure differences between trial 
arms. 
Results  
Spironolactone did not reduce stiffness, with evidence for reduced CAVI on doxazosin 
rather than spironolactone (mean difference [95% confidence intervals]; 0.25[-0.3, 0.5] 
units, p=0.080), firmer for PWVart (0.37[0.01, 0.7] ms-1, p=0.045). There was no 
difference in systolic pressure reduction between spironolactone and doxazosin (0.7[-
4.8, 3.3]mmHg, p=0.7).  Circulating nitrate and nitrite increased on active versus 
placebo juice, with central systolic pressure lowered -2.6[-4.5, - 0.8]mmHg, p=0.007 
more on the active juice, but did not reduce CAVI, PWVart, nor peripheral pressure.  
Change in nitrate and nitrite concentrations were 1.5-fold [1.1-2.2] and 2.2-fold [1.3, 
3.6] higher on spironolactone than on doxazosin respectively; both p<0.05. 
Conclusion 
Contrary to our hypothesis, in at-risk/type-2 diabetes patients, spironolactone did not 
reduce arterial stiffness, rather PWVart was lower on doxazosin. Dietary nitrate 
elevated plasma nitrite, selectively lowering central systolic pressure, observed 
previously for nitrite. 
 
Clinical trial registration: ISRCTN registry: ISRCTN25003627/ DOI 
10.1186/ISRCTN25003627. 
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Statement 1: What is already known about this subject 
- Arterial stiffness is a predictor of mortality, independently of BP and diabetes 
- Inorganic dietary nitrate has been shown to reduce blood pressure and arterial 
stiffness via the nitrate-nitrite, nitric oxide pathway 
- Spironolactone is reported to reduce arterial stiffness, but if this is BP-
independent is not clear  
Statement 2: What this study adds  
- The longest trial to test inorganic nitrate on vascular parameters to date 
- Inorganic dietary nitrate selectively reduced central systolic BP which parallels 
previous data 
- Despite lowering BP slightly more than did the -blocker, doxazosin, 
spironolactone did not reduce arterial stiffness, which was marginally lowered 
on doxazosin 
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Introduction 
Type 2 diabetes mellitus (T2DM) is characterized by excess cardiac and vascular disease 
even before ‘formal’ diagnosis [1,2]. Arterial stiffness measured as aortic pulse wave 
velocity (PWVart) is amongst the most powerful 21predictors of both cardiovascular 
and all-cause mortality, crucially independent of mean or systolic blood pressure (SBP) 
and other standard risk factors, including glycaemia [3]. Reducing arterial stiffness 
could be particularly valuable in overweight people at increased risk of or already with 
overt T2DM, because of its predictive impact in glucose intolerance/ T2DM [4], and its 
high prevalence in these people since early measures of arterial stiffness were used [5-
7]. The pathology of arterial stiffness involves elastin degradation and collagen 
deposition with fibrosis from inflammatory stimuli including dysregulation of nitric 
oxide (NO) [8] and up-regulation of pro-fibrotic factors [9-11]. 
 
Reductions in PWV by lifestyle measures are reported particularly for exercise, weight 
loss and specific dietary components, and by various pharmacological agents, including 
anti-hypertensives, statins, some anti-diabetic medications and advanced glycation end-
product breakers [12].  However, PWV reduction formally independent of BP is seldom 
examined. Doing so is important as PWV is intrinsically linked to BP hence it can be 
hard to distinguish the two. 
 
Spironolactone, a mineralocorticoid receptor antagonist was recently found highly 
effective in reducing BP in proven resistant hypertension [13].  Initial trials for 
specifically reducing arterial stiffness, in early kidney disease [14], untreated 
hypertensives [15] and dilated cardiomyopathy [16] appeared promising. These trials 
were generally not designed to test impact on PWV formally independent of BP change. 
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Inorganic (dietary) nitrate, abundant in green leafy vegetables and beetroot [17] 
reduces BP in healthy [18] and hypertensive volunteers [19] via the nitrate-nitrite-NO 
pathway [20], but not in patients with T2DM, [21-22] or with their inclusion in a meta-
analysis of 24h ambulatory BP monitoring  [23].  PWV reductions with inorganic 
(dietary) nitrate have also been noted in healthy and hypertensive volunteers, but over 
too short a period for vessel remodelling; these were likely BP-dependent reductions 
[24]. We found that inorganic nitrite selectively lowers aortic, relative to peripheral, BP, 
with reductions also in PWV that seem to be via selective normoxia-dependent conduit 
(radial) artery dilatation in healthy volunteers [25-26], and selectively dilated epicardial 
coronary arteries in patients undergoing coronary angiography [27]. While tolerance 
develops to organic nitrates [28], it has not been described for inorganic (dietary) 
nitrate [19], perhaps this due to the mechanisms of bioactivation of inorganic nitrite to 
nitric oxide, and suppression of reactive oxygen species (ROS)[29]. Longer-term effects 
of inorganic (dietary) nitrate beyond 6 weeks have not yet been tested. 
 
In the trial reported here, we hypothesised that spironolactone and dietary nitrate 
would reduce arterial stiffness independently of BP reduction in people with or at risk 
of T2DM. We tested this hypothesis in a double-blind, controlled, factorial design 24-
week trial using cardio-ankle vascular index (CAVI) as the primary measure of stiffness 
and PWVart adjusted for BP change as the secondary outcome. 
 
Methods 
Study design and interventions 
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A single centre, double-blind, parallel, randomised controlled intervention trial in a 2 x 
2 factorial design was carried out in accordance with the Declaration of Helsinki and 
U.S. Code of Federal Regulations.   
Participants were assigned to one of 4 arms using computer randomization in blocks of 
6, by an independent party. Interventions were spironolactone (12.5mg daily for 1 
week, 12.5mg twice daily for 11 weeks, increased to 25mg twice daily to 24 weeks) with 
doxazosin as its control (4mg similarly titrated to 8mg twice daily) and dietary nitrate 
as beetroot juice (7.5mmol nitrate increased at 12 weeks to 11.2mmol nitrate, as 
measured in our lab) or nitrate-free beetroot juice as placebo (0mmol nitrate), (see 
Supplementary text).  Spironolactone and doxazosin were prepared in indistinguishable 
brown bottles by St Thomas’ Hospital pharmacy, London, UK.  Commercially available 
beetroot juice, ‘Beet It’ and ‘Beet It SPORT’ were supplied as 15 x 70 mL bottles, 
indistinguishable between active and control juice, prepared and supplied by James 
White Drinks, Ltd, Suffolk UK. 
 
Participants with or at risk of T2DM were recruited from Guy’s and St Thomas’ 
Hospitals, London, UK and surrounding areas between 2013-2015.  Inclusion criteria 
were age 18-80years, clinically diagnosed T2DM or at risk of T2DM (as body mass index 
(BMI) ≥27 kg/m2, positive family history or glucose intolerance after 75g challenge), 
ability to understand and comply with the protocol.  Exclusion criteria: interfering 
chronic illness, adverse reaction to either drug, known allergy to beetroot, eGFR < 45 
mL min-1, HbA1c >11% (97mM/M), pregnant, breast feeding or atrial fibrillation.  
Written informed consent was obtained from all participants.  The protocol was 
approved by South London Research Ethics Committee.  
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The primary outcome was change in arterial stiffness, nominally independent of BP, as 
measured by CAVI.  Secondary outcomes were arterial stiffness, as measured by 
PWVart, with central BP and augmentation index.  Both primary and secondary 
outcomes were to be adjusted for differences in peripheral baseline BP and BP change 
between trial arms, start-finish.  
At St Thomas’ Hospital Clinical Research Facility, London, participants rested supine in a 
temperature-controlled room for 20 minutes.  Vascular measures were then performed 
supine in random order according to institutional guidelines.  
 
After anthropometry, CAVI was measured using the VS-1500N, VaSera machine (Fukuda 
Denshi Ltd, Japan) as described [30].  Microphone-detected heart sounds were 
monitored, with BP cuffs on each arm and above each ankle, with pulse waves detected 
by the cuffs at 30-50mmHg. CAVI was calculated from PWV, as pulse wave transit times 
from aortic valve (2nd sound) to ankle: CAVI= [ln SBP/ln DBP]. [2ρ/ΔP]. PWV2, with path 
length estimated from height [31]. CAVI was measured in duplicate and averaged. CAVI0 
data were calculated as described previously [32].  PWVart, peripheral systolic, diastolic 
and central BP, aortic and brachial augmentation index and heart rate from 6-8 cardiac 
cycles were measured using appropriately sized cuffs by Arteriograph 24TM device 
(TensioMed Kft. Hungary), analysing mean of duplicate good quality readings. Quality 
was pre-specified with Arteriograph and VaSera waveforms checked by the 
manufacturers, blinded to other data. PWV with standard deviations (SDs) >1 were 
excluded.   
 
Non-fasted blood (Hb, HbA1c, plasma glucose, sodium, potassium, creatinine, 
aldosterone and renin mass concentrations) and urinary sodium, potassium, creatinine 
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were measured by our accredited laboratory.  Plasma nitrate and nitrite concentrations 
were measured by chemiluminescence as described [25,33]. 
 
Statistical analysis 
Sufficient data from CAVI interventions were not available for sample size calculations.  
We used previous studies on BP with beetroot juice [33-34]and the 1-year study of 
PWVart on spironolactone [14] aiming to detect a 20% reduction over 6 months in PWV 
(standard deviation (SD) 8%) with minimum 80% power, at p<0.05.  We estimated we 
needed 24 participants per each of 4 arms, aiming for 30 per group allowing for 20% 
drop out, for 24 patients in each to finish the trial. 
 
A modified intention-to-treat analysis was performed using SAS (version 9.3); data are 
presented as least-square means estimated from mixed effects models (log-transformed 
where not normally distributed), adjusted as pre-specified for baseline, and any 
difference in final SBP change between the two arms being analysed. To estimate 
independence from BP change, changes in PWVart were adjusted for change in SBP. 
Least square mean data were averaged over the 2 follow-up visits (3 and 6 months). 
Regression analyses assumed linear relationships, with some predictor variables (renin, 
nitrate and nitrite) log-transformed.  
 
Results 
Baseline 
Of 154 patients eligible and agreeing to attend, 11 were not eligible (4 for high HbA1c, 2 
for previous adverse reactions, 2 with atrial fibrillation, 3 for ill health); 17 then 
declined to participate.  The remaining 126 participants were randomised 
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(Supplementary Figure 1).  Baseline characteristics were generally well-matched 
between arms (Table 1 and Supplementary Table 1) both between drugs and by 
nitrate/nitrate-free juices (Tables 2-3).  Of randomized participants, 62% had T2DM 
with mean HbA1c 50mM/M (6.7%). The remaining 38% were ‘at risk’ (mean HbA1c <40 
mM/M, 5.8%, BMI 32.5kg/m2).  
 
Follow up   
Time from randomization to midpoint dose increase was 13±3 weeks and from 
midpoint-final visit 12±3weeks, totaling 24±5 weeks from randomization to end-of-
study. Between baseline and 12 weeks’ follow-up, 16 participants dropped out (6 no 
reason, 1 unrelated illness, 4 not re-contacted and 5 with side effects: 2 dizziness, 2 
elevated glucose, 1 breathlessness). There were no follow-up measures for these 
participants. 
 
Treatment effects 
No statistical interactions occurred between beetroot or placebo juice arms and the 
spironolactone vs. doxazosin arm for any of the main/ haemodynamic outcomes, so 
data are presented separately (Tables 2-3).  Supplementary Table 1 shows absolute, 
unadjusted changes of vascular and biological parameters for the 4 arms. 
 
SPIRONOLACTONE VS. DOXAZOSIN: In adjusted models, spironolactone and doxazosin 
reduced BP similarly (SBP, least-square mean [95% CI]: -7.0 [-9.9, -4.2] vs. -6.3 [-9.1, -
3.5] mmHg respectively, p= 0.7, Figure 1C and diastolic (DBP), -5.6 [-7.4, -3.7] vs. -4.7 [-
6.5, -2.9] mmHg respectively, p= 0.5, Supplementary Figure 2A). The direction in 
difference for the primary endpoint, change in CAVI between drugs, was contrary to our 
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hypothesis, borderline significant towards doxazosin (0.14 [-0.06, 0.34] vs. -0.11 [-0.30, 
0.08] units p=0.08, for spironolactone and doxazosin respectively, Figure 1A).  When 
transposed to CAVI0, our data was not significant -0.04(-0.44, 0.35) vs. 0.24 (-0.19, 0.67), 
p= 0.34 (doxazosin vs. spironolactone)[19]. However, the difference in PWVart change 
between spironolactone and doxazosin was significant (-0.07 [-0.33, 0.18] vs. -0.44 [-
0.69, -0.19] ms-2, p=0.045, Figure 1B) towards doxazosin, again contrary to our 
hypothesis. There were also no other differences in other hemodynamic parameters 
estimated by the Arteriograph for the drug arm, in central BP (-7.6 [-9.0, -6.3] vs. -7.2 [-
8.5, -5.9] mmHg, p=0.6; Figure 1 D), augmentation index (Supplementary Figure 2 B-C), 
or heart rate.  
Although no drug/ juice interactions in terms of hemodynamic variables were noted, 
nitrate and nitrite concentrations were higher on spironolactone than on doxazosin by 
1.5-fold [1.1-2.2] and 2.2-fold [1.3, 3.6] respectively; both p<0.05; see Figure 1 E-F.  
Unadjusted data are in Supplementary Table 1. 
 
BEETROOT VS. PLACEBO JUICE: There were no adjusted differences in change in 
arterial stiffness change as CAVI (0.02 [-0.18, 0.21] vs. 0.01 [-0.18, 0.21], p=0.98, Figure 
2A) CAVI0 0.12(-0.29, 0.53) vs. 0.08(-0.34, 0.50), p= 0.898 (active vs. control) [19] nor 
PWVart (-0.23 [-0.48, 0.01] vs. -0.28 [-0.54, -0.03], p=0.8, Figure 2B), nor in 
brachial BP between active and placebo juice (SBP, -6.4 [-9.2, -3.6] vs. -6.9 [-9.8, -4.0] 
mmHg, p= 0.8, Figure 2C, nor DBP, p= 0.9 (Supplementary Figure 3A). However, 
difference in change in central (aortic) SBP between active and control juices was highly 
significant (-8.7[-10, -7.4] vs. -6.1[-7.4, -4.8] mmHg, p=0.007, Figure 2D).  Decreases in 
aortic (-3 [-5.1, -0.9] vs. -0.3 [-2.4, 1.9] %, p=0.08) and brachial augmentation index (-5.9 
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[-10.0, -1.76] vs. -0.49 [-4.72, 3.74] %, p=0.08) were also borderline (Supplementary 
Figure 3B-C).   
Plasma nitrate levels rose as expected in those on active compared with placebo juice (a 
4.3[3.4, 5.5]-fold increase vs. 1.3[1.02, 1.71], p<0.001, Figure 2 E); nitrite levels 
increased 1.6[1.1, 2.2]-fold vs. 0.9[0.6, 1.2], p=0.02, Figure 2 F). These data confirm 
adherence to the beetroot juice arm. Unadjusted data are in Supplementary Table 1. 
 
Adverse effects 
From randomization, all adverse effects were documented and assessed after 
unblinding, which did not occur until after the trial finished.  Of 126 participants 
randomized, 12 reported effects deemed to be related to the drug interventions (5 
dizziness of whom 4 taking doxazosin, 2 rashes (1 taking spironolactone), 1 reported 
incontinence (doxazosin), nausea (spironolactone), heartburn (spironolactone), 
tachycardia (doxazosin), breathlessness (spironolactone)).  In 8 of these patients, doses 
were adjusted or stopped; one participant willingly tolerated the effects.  Throughout 
the study 5 patients withdrew consent due to adverse effects, 3 deemed related to the 
intervention (2 dizziness, 1 breathlessness); 1 patient reported dyspepsia, deemed 
related to juice.  No participants were excluded.   
 
Further regression analyses 
Relationships between baseline plasma renin, nitrate and nitrite and change in CAVI, 
PWVart and central BP (from baseline to follow-up) were examined. Change in central 
BP was significantly related to baseline plasma renin (r= 0.36, p<0.001), so that for a 10-
fold reduction in plasma renin, there was an 8.6 mmHg greater fall in central BP (Figure 
3C).  This result was not specific to either the drug or juice arm.  There were no 
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relationships between change in CAVI or PWVart and renin (r=0.02, p=0.8, and r=0.05, 
p= 0.6, respectively - Figure 3A-B).  There were also no relationships between change in 
CAVI, PWVart or central BP and nitrate (Supplementary Figure 4 A-C; r=0.07, p=0.6; r= -
0.04, p= 0.7; r=0.01, p=0.9, respectively) or nitrite (Supplementary Figure 5A-C; r=0.13, 
p=0.3; r= 0.02, p= 0.87; r=-0.06, p=0.7, respectively). 
 
 
Discussion 
This randomized trial demonstrated a proof of concept that reduction of arterial 
stiffness, an independent predictor of mortality generally and in T2DM [4], could be 
measured and estimated independently of BP, as measured by CAVI and PWVart, 
adjusting for differences in achieved BP between trial groups.  
Spironolactone versus doxazosin 
The reduction in CAVI, which measures cardiac-ankle PWV, including a long more 
muscular arterial path, was borderline (p=0.07). However, contrary to our hypothesis, 
the result was in the opposite direction, towards the doxazosin, not the spironolactone 
arm. The consistency and direction of this effect on arterial stiffness was supported, 
again independent of BP change, by the significant impact on central PWVart, our other 
main outcome. Unlike aortic PWV measured as carotid-femoral [3] or down just the 
descending aorta [6], PWV in the extremities, down muscular arterial pathways such as 
the femoral- posterior tibial or cardiac-brachial routes, does not predict outcomes [34]. 
However, the ease of CAVI/ PWV measurement using the multi-cuff arm-ankle method, 
which includes the central aorta, and the microphone-detected 2nd sound timing for the 
precise initiation of the pressure/flow wave outweighs issues of including extremity 
pathways in its measurements. BP independence of CAVI has been discussed and re-
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formulated to produce CAVI0 [32,36]; when we transposed our data based on CAVI0 
suggested by Spronk et al they were not significant [37]. 
 
Here, adequate daily doses of ≤16 mg doxazosin, as alpha receptor blockade, were 
compared with ≤50 mg spironolactone, as mineralocorticoid receptor antagonist. Our 
results contrast with previous work, which suggested spironolactone at just 25 mg 
reduced PWV by 0.8 m/s versus placebo, apparently with little change in BP 14, in 
patients with mild kidney impairment; in that study, spironolactone had been added to 
angiotensin converting enzyme inhibitors and angiotensin receptor blockers. While the 
change in PWV and aortic distensibility was significant, so also was the change in either 
24-hour ambulatory, or in office systolic BP; i.e.: one was not independent of the other.  
Left ventricular (LV) mass also changed, likely in response to the decrease BP. In our 
study, we found that LV mass index between the 2 active BP drugs was not significant 
[38]. Here, 71% patients were on prior anti-hypertensive medication of many types, and 
the 62% with T2DM generally on metformin and other glucocentric agents.  The 
difference in change of (office) BP was not significant, despite adjusting for the small 
change in favour of spironolactone. Although there are suggestions that doxazosin may 
reduce arterial stiffness [39-40], neither of those studies was a formal trial nor adjusted 
for any BP change, and its use in arterial function has not to our knowledge been 
examined in T2DM. From a physiological point of view the action of doxazosin can be 
easily explained. Vascular tone does influence arterial stiffness in muscular arteries [41-
42] and is likely to have a similar action in larger arteries (although this influence is 
difficult to assess due to concomitant effect in BP). 
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The absolute reduction in BP for those who finished 6 months’ treatment was a similar 
7 mmHg SBP reduction in both drug groups, but the least square mean fall in BP was a 
non-significantly greater 2.3 mmHg on spironolactone than doxazosin, using a higher 
dose than in our recent blinded, rotational Pathway Trial where the difference was 4.5 
mmHg [13]. The different patient population and the lower dose of doxazosin likely 
contributed to different treatment responses there to here. 
 
Results from the anti-hypertensive ALLHAT Trial are relevant; its doxazosin arm had to 
be stopped after ~2 years, due to excess heart failure and other cardiac events [43]. 
Having diabetes on doxazosin in the trial was a particular aggravating factor [44]. 
Whilst the change in PWVart and the borderline change in CAVI could be related to 
changes in cardiac function, our echocardiographic data [38] do not suggest that as the 
ejection fraction (EF), and global longitudinal strain (GLS) which is a well established 
markers of systolic function, were similar between the two drugs  in our study; 
however, S’ (a tissue-Doppler systolic function index) was increased by spironolactone 
versus doxazosin. Thus, while our data suggest we have shown ‘proof of concept’ that 
PWVart can be reduced independent of BP change, we have not shown it is independent 
of cardiac functional change.  
Effects of inorganic nitrate 
No effect of active (nitrate containing) beetroot juice, even at higher dose, was found on 
peripheral (brachial) BP, CAVI or PWV consistent with two previous dietary nitrate 
studies in patients with diabetes [21-22] and in line with our recent results that acute 
physiological elevations of plasma glucose and insulin, following an oral glucose 
tolerance test, result in a lack of BP-lowering with dietary nitrate in healthy adults [45]. 
Previous reductions in PWV were with peripheral BP reductions [22]; the lack of change 
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in peripheral BP with nitrate may underlie the lack of effect on PWV, suggesting dietary 
nitrate has no direct effect on arterial stiffness. Further the lack of reduction on PWV 
with dietary nitrate is in line with acute effects seen previously with glyceryl trinitrate 
[46]. Plasma nitrate and nitrite did increase, some 4-fold and only 2-fold respectively. 
The two other diabetes studies [21-22] also found significant increases in plasma nitrite 
similar to that in healthy participants [33] and hypertensives [19].  
 
Central SBP decreased on nitrate-containing juice, with similar if borderline changes in 
augmentation index, simultaneous to the significant rise in plasma nitrite, without 
peripheral BP changes. Although this could be as a result of venodilation with reduced 
preload, indeed decreased central SBP was observed with decreased preload (induced 
by lower limb venous occlusion) [47], in an echocardiogram sub-study (data not 
presented here), we saw only very small differences in stroke volume between 
treatments and so, although it might be contributory this is unlikely to be an alternative 
mechanism [38]. This selective central SBP change is entirely consistent with our 
previous findings of normoxia-dependent conduit artery dilatation after inorganic 
nitrite, selectively reducing central SBP [28]. A measurable increase in plasma nitrite in 
healthy volunteers also led to decreased brachial-femoral PWV, independently of 
peripheral BP [28]. A different more muscular brachial conduit artery arterial path was 
studied there. However, whether currently measured central BP has clinical impact 
beyond peripheral BP in the general population, as some claim [48], remains uncertain, 
as recently reported from Framingham [49], in part related to calibration issues [50-
51]. However, central aortic pressure may be especially relevant in specific populations, 
such as HFpEF [52].  
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The confirmation of a central BP effect here, as found previously, suggests that testing 
for central aortic stiffening changes, affecting the aortic root, ascending aorta or arch 
using other imaging methods including MR could be revealing. Other recent 
Framingham work confirms that rather than flow-mediated dilation per se, poorer 
forearm hyperemic mean blood flow velocity reflecting microvascular (smaller 
resistance vessel) changes underlies some 8-13% of the overall stiffening effect 
measured by PWV that predicts outcomes powerfully and independently of BP in that 
cohort [53].  
 
Despite observing no drug/ juice interactions in hemodynamic parameters, there was 
an interesting finding of increased plasma nitrate and nitrite concentrations observed 
on spironolactone versus doxazosin. This could be related to spironolactone’s diuretic 
effect, hemo-concentrating nitrate and nitrite, relative to the vasodilatory effect of 
doxazosin, or via altering renal nitrate/nitrite excretion; unfortunately the latter was 
not assessed in this study.  
 
 
Adverse events attributable to the blinded interventions were small and minor, with 
one person mentioning some increased reflux/acidity on the active, nitrate containing 
beetroot juice. Potassium retention on spironolactone was not a problem at all, 
probably because entry excluded people with eGFR values of <45mL.min.  
 
This was intentionally a pragmatic trial testing general efficacy of the interventions. In 
retrospect, the choice of doxazosin as the control antihypertensive agent for 
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spironolactone could be disputed, but few other drugs currently balance dosage and 
effect equivalently. Medication timing over the 6 months, and adherence to respective 
treatments could not be assured, although changes in nitrate concentrations on active 
juice suggested reasonable adherence to the juice overall. Participants were asked to 
take their treatment and juice on rising or around breakfast-time, since peak plasma 
nitrite concentrations after dietary nitrate ingestion occurs about 2.5 hours later [18]; 
however, the intervals between juice ingestion and visits to the Clinical Research 
Facility and hence blood collection may have been highly variable. Measurements were 
all made under standardized conditions in a Clinical Research Facility. We also 
recognize the limitation in our sample size calculation being based on PWV, and not 
CAVI, the primary outcome of the research; this was due to sufficient data not being 
available at the time of starting the trial. 
 
Contrary to our hypothesis, arterial stiffness was not reduced on spironolactone, rather 
that occurred on the doxazosin arm independently of BP, as measured by PWVart, with 
a similar borderline effect on the longer muscular arterial pathway estimated by CAVI, 
in these patients with or at risk of T2DM. Whilst active nitrate-containing beetroot juice 
had no effect on arterial stiffness, central BP was significantly reduced by nitrate-nitrite. 
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Figure 1.  Change in vascular parameters in response to spironolactone and doxasozin 
Change in cardio-ankle vascular index, aortic pulse wave velocity, systolic, and central 
blood pressure and plasma nitrate and nitrite concentration on drug intervention 
Data are least square means averaged over the two follow up visits with mean, 95% confidence intervals.  
* is p<0.05. A, CAVI  (cardio-ankle vascular index), B, PWV (pulse wave velocity by Arteriograph), C, SBP 
(systolic blood pressure), D, aoSBP (aortic systolic blood pressure), E, [nitrate] (plasma nitrate 
concentration), F, [nitrite] (plasma nitrite concentration). 
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Figure 2.  Change in vascular parameters in response to inorganic nitrate from beetroot 
juice and nitrate free, placebo beetroot juice 
Change in cardio-ankle vascular index, aortic pulse wave velocity, systolic, and central 
blood pressure, aortic and brachial augmentation index and plasma nitrate and nitrite 
concentration on juice intervention. 
Data are least square means averaged over the two follow up visits with mean, 95% confidence intervals.  
* is p>0.05, ** is p< 0.01, *** is p<0.001. A, CAVI  (cardio-ankle vascular index), B, PWV (pulse wave velocity 
by Arteriograh), C, SBP (systolic blood pressure), D, aoSBP (aortic systolic blood pressure), E, [nitrate] 
(plasma nitrate concentration) F, [nitrite] (plasma nitrite concentration). 
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Figure 3. Correlation between change in vascular parameters and baseline plasma renin 
Change in CAVI (A), PWV (B) and central BP (C) vs. baseline plasma nitrite concentration 
PWV (pulse wave velocity by Arteriograph), BP (blood pressure), CAVI (cardio-ankle vascular index), n=64. 
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Table 1. Mean (with standard deviation) baseline characteristics of patients 
randomized into the VaSera trial 
 Spironolactone Doxazosin 
Juice: Active 
(n= 35) 
Placebo 
(n= 30) 
Active 
(n= 29) 
Placebo 
(n= 33) 
Age, years 56.9 (13.9) 56.3 (11.0) 57.6 (12.3) 55.9 (14.0) 
Female, n (%) 11 (31.4) 11 (36.7) 13 (44.8) 11 (33.3) 
Weight, kg 96.4 (15.0) 94.8 (15.2) 98.1 (19.7) 88.4 (19.9) 
Height, m 1.69 (0.10) 1.70 (0.10) 1.71 (0.10) 1.72 (0.12) 
BMI, kg/m2 33.9 (4.9) 33.0 (4.8) 33.3 (6.1) 30.2 (6.1) 
Waist, cm 112 (29) 110 (10) 112 (13) 103 (14) 
T2DM, n (%) 18 (51.4) 20 (66.7) 18 (62.1) 22 (66.7) 
eGFR, mL/min/1.73m2 a 81 (25) 80 (17) 84(23) 84 (18) 
Patients treated with     
Metformin, n (%) 12 (36.4) 15 (50.0) 15 (51.7) 15 (46.9) 
Insulin, n (%)  5 (14.7) 8 (26.7) 2 ( 6.9) 8 (24.2) 
Other oral diabetic medication, 
n (%)  
6 (17.6) 7 (23.3) 7 (24.1) 6 (18.2) 
Anti hypertensive, n (%) b 20 (57.1) 20 (66.7) 25 (86.2) 24 (72.7) 
Mean number of 
antihypertensives, n (%)c 
1.6 (0.7) 1.9 (0.9) 1.7 (0.8) 1.7 (0.6) 
Diuretics, n (%)  5 (14.7) 10 (33.3) 9 (31.0) 13 (40.6) 
Statins, n (%) 15 (44.1) 15 (50.0) 17 (58.6) 15 (45.5) 
 
‘Active’ is nitrate containing beetroot juice; ‘placebo’ is nitrate depleted beetroot juice.  
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Values are mean (standard deviation) unless stated otherwise. a Calculated using abbreviated MDRD 
equation, b represents those taking at least one anti hypertensive, c represents mean number of anti 
hypertensive drugs taken of those taking at least one 
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Table 2.  Mean (with 95% confidence interval) vascular, plasma and urine parameters 
at baseline and follow-up visits for spironolactone and doxazosin 
 
Baseline Midpoint End 
Spironolactone Doxazosin Spironolactone Doxazosin Spironolactone Doxazosin 
Vascular       
CAVI, units 8.35(8.02,8.67) 8.07(7.68,8.47) 8.37(8.08,8.67) 8.05(7.57,8.52) 8.19(7.81,8.57) 8.04(7.56,8.52) 
PWVart, ms-
2 9.4(8.9,9.9) 9.7(9.1,10.2) 9.3(8.8,9.7) 8.9(8.4,9.4) 9.3(8.9,9.7) 9.3(8.8,9.9) 
SBP, mmHg 143.4(138.3,148.
4) 
140.1(136.2,144.
0) 
137.2(132.4,141.
9) 
136.7(132.1,141.
3) 
135.0(131.1,139.
0) 
137.7(132.7,142.
7) 
DBP, mmHg 88.0(84.7,91.2) 86.8(84.7,88.9) 84.5(81.8,87.1) 84.5(82.0,87.1) 82.6(79.5,85.7) 84.8(82.0,87.7) 
aoSBP, 
mmHg 
135.4(129.1,141.
6) 
130.0(123.7,136.
3) 
126.6(120.5,132.
7) 
125.0(119.5,130.
5) 
123.7(118.3,129.
2) 
123.9(119.2,128.
6) 
brAIX, % -16.4(-24.8,-7.9) -22.7(-31.6,-13.8) -22.4(-30.2,-14.6) -22.6(-32.7,-12.4) -24.6(-32.9,-16.2) -24.2(-32.7,-15.7) 
aoAIX, % 29.4(25.1,33.6) 26.1(21.6,30.6) 26.3(22.3,30.2) 26.2(21.1,31.4) 25.2(21.0,29.4) 25.4(21.1,29.7) 
HR, bpm 69.9(66.6,73.2) 71.7(68.2,75.2) 69.3(66.4,72.1) 69.6(66.5,72.6) 71.4(68.2,74.5) 69.6(66.3,72.9) 
Plasma       
Glucosea, 
mmol/L 6.4(5.8,7.0) 6.2(5.6,6.8) 7.1(6.3,8.0) 6.3(5.6,7.2) 6.7(5.8,7.8) 6.0(5.3,6.8) 
HbA1ca, % 6.7(6.3,7.0) 6.7(6.4,7.0) 6.9(6.6,7.3) 6.7(6.4,7.1) 6.8(6.4,7.2) 6.7(6.3,7.1) 
Sodium, 
mmol/L 
139.7(139.0,140.
3) 
139.7(139.0,140.
4) 
138.2(137.4,139.
0) 
140.0(139.3,140.
7) 
138.4(137.5,139.
4) 
139.7(139.0,140.
4) 
Potassium, 
mmol/L 4.27(4.16,4.39) 4.18(4.07,4.30) 4.53(4.42,4.64) 4.21(4.09,4.34) 4.60(4.49,4.72) 4.17(4.07,4.28) 
Creatininea 
μmol/L 81.6(76.6,87.0) 81.4(75.9,87.3) 83.1(77.4,89.3) 83.7(78.5,89.2) 84.7(78.5,91.4) 83.4(78.0,89.1) 
Renina, 
mU/mL 31.8(18.7,54.0) 31.5(20.2,49.2) 63.2(38.5,103.7) 38.3(21.6,67.9) 66.1(39.3,111.4) 39.2(22.1,69.8) 
Aldosterone
a,  pmol/L  225(191,264) 229(199,264) 439(367,525) 281(241,327) 391(325,470) 300(251,358) 
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Baseline Midpoint End 
Spironolactone Doxazosin Spironolactone Doxazosin Spironolactone Doxazosin 
Nitratea, μM 37.4(29.6,47.4) 25.2(19.0,33.6) 78.1(55.8,109.4) 62.4(43.5,89.5) 97.8(66.5,144.0) 54.2(35.9,81.9) 
Nitritea, nM 0.189(0.123,0.28
9) 
0.147(0.098,0.22
2) 
0.268(0.177,0.40
5) 
0.133(0.076,0.23
3) 
0.242(0.146,0.40
0) 
0.115(0.065,0.20
3) 
Urine       
Sodiuma, 
mmol/L 61.9(53.1,72.2) 64.0(52.7,77.8) 64.1(53.8,76.4) 64.6(53.1,78.5) 78.3(65.5,93.5) 70.0(58.8,83.5) 
Potassiuma, 
mmol/L 50.4(43.4,58.5) 57.2(48.3,67.8) 66.1(56.5,77.5) 62.5(53.3,73.3) 61.6(52.0,73.0) 70.2(60.8,81.0) 
Creatininea, 
mmol/L 7.99(6.60,9.68) 9.21(7.45,11.38) 8.86(7.34,10.70) 
10.57(8.53,13.08
) 8.09(6.71,9.75) 
10.58(8.77,12.76
) 
*Analyzed in log units and geometric means presented. 
PWVart, pulse wave velocity by Arteriograph; aoSBP, aortic blood pressure; aoAix aortic augmentation 
index; bpm, beats per minute; brAix, brachial augmentation index; CAVI, cardio-ankle vascular index; 
DBP, diastolic blood pressure; HR heart rate; SBP, systolic blood pressure. Values are mean (95% 
confidence interval) 
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Table 3.  Mean (with 95% confidence interval) vascular, plasma and urine parameters at 
baseline and two follow up visits for nitrate containing (active) and nitrate depleted 
(placebo) beetroot juice 
 
Baseline Midpoint End 
Active Placebo Active Placebo Active Placebo 
Vascular       
CAVI, units 8.28(7.92,8.64) 8.14(7.77,8.51) 8.29(7.91,8.67) 8.13(7.72,8.54) 8.15(7.71,8.58) 8.08(7.65,8.52) 
PWVart, ms-
2 9.7(9.1,10.3) 9.4(8.9,9.8) 9.3(8.8,9.8) 8.9(8.5,9.4) 9.5(9.0,9.9) 9.2(8.7,9.7) 
SBP, mmHg 142.5(137.7,147.
3) 
140.9(136.7,145.
1) 
137.5(132.8,142.
3) 
136.4(131.7,141.
1) 
136.2(131.9,140.
4) 
136.7(131.9,141.
5) 
DBP, mmHg 88.5(85.6,91.5) 86.3(83.8,88.7) 84.4(81.5,87.2) 84.6(82.2,87.0) 83.4(80.7,86.1) 84.1(80.9,87.3) 
aoSBP, 
mmHg 
134.8(128.8,140.
8) 
130.6(124.0,137.
1) 
127.2(121.1,133.
4) 
124.4(118.9,129.
9) 
123.9(119.2,128.
5) 
123.8(118.3,129.
2) 
brAIX, % 
-13.5(-21.5,-5.5) 
-25.7(-34.8,-
16.6) 
-20.4(-28.7,-
12.2) 
-24.5(-34.1,-
14.8) 
-23.2(-31.4,-
15.0) 
-25.6(-34.3,-
16.9) 
aoAIX, % 30.8(26.7,34.9) 24.6(20.0,29.2) 27.3(23.1,31.5) 25.3(20.4,30.1) 25.9(21.8,30.0) 24.7(20.3,29.1) 
HR, bpm 68.5(65.5,71.5) 73.0(69.3,76.7) 68.8(66.0,71.7) 69.9(66.9,73.0) 71.8(68.6,75.1) 69.1(66.0,72.2) 
Plasma       
Glucosea 
mmol/L 5.91(5.36,6.52) 6.64(6.05,7.29) 7.04(6.15,8.05) 6.45(5.76,7.21) 6.49(5.66,7.45) 6.21(5.44,7.08) 
HbA1ca, % 6.63(6.30,6.97) 6.73(6.43,7.04) 6.81(6.42,7.23) 6.87(6.57,7.18) 6.65(6.24,7.09) 6.85(6.52,7.19) 
Sodium, 
mmol/L 
139.9(139.2,140.
5) 
139.5(138.8,140.
2) 
138.8(138.0,139.
7) 
139.3(138.6,140.
1) 
139.1(138.2,140.
0) 
139.0(138.1,139.
8) 
Potassium, 
mmol/L 4.26(4.15,4.37) 4.20(4.08,4.33) 4.46(4.32,4.59) 4.32(4.20,4.43) 4.41(4.28,4.55) 4.38(4.26,4.49) 
Creatininea 
μmol/L 81.3(75.4,87.6) 81.7(77.1,86.7) 83.4(77.1,90.3) 83.4(78.8,88.2) 85.3(78.6,92.5) 82.9(78.1,87.9) 
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Baseline Midpoint End 
Active Placebo Active Placebo Active Placebo 
Renin†, 
mU/mL 23.5(14.7,37.6) 42.6(26.0,69.8) 41.6(24.7,70.0) 57.4(33.0,99.7) 49.8(29.6,83.7) 54.7(30.4,98.6) 
Aldosterone
a,  pmol/L  230(200,266) 224(190,263) 337(281,406) 363(305,431) 375(318,442) 319(260,391) 
Nitratea, μM 
28.8(22.5,36.9) 32.4(24.2,43.4) 
125.4(94.0,167.3
) 43.4(32.5,58.1) 
118.0(82.4,169.0
) 35.9(25.7,50.0) 
Nitritea, nM 0.191(0.130,0.28
2) 
0.144(0.092,0.22
6) 
0.268(0.168,0.42
8) 
0.139(0.083,0.23
3) 
0.219(0.135,0.35
3) 
0.107(0.056,0.20
3) 
Urine       
Sodiuma, 
mmol/L 66.2(54.4,80.6) 60.0(51.7,69.6) 66.9(54.9,81.5) 61.8(52.0,73.3) 79.7(67.3,94.3) 68.9(57.3,82.9) 
Potassiuma, 
mmol/L 51.6(44.2,60.1) 55.4(47.0,65.3) 63.0(53.2,74.7) 65.3(56.3,75.8) 65.8(56.9,76.0) 65.6(55.1,78.1) 
Creatininea, 
mmol/L 8.96(7.35,10.93) 8.18(6.67,10.03) 9.58(7.82,11.73) 9.77(7.97,11.98) 9.28(7.68,11.22) 9.12(7.51,11.06) 
*Analyzed in log units and geometric means presented 
 ‘Active’ is nitrate containing beetroot juice; ‘placebo’ is nitrate depleted beetroot juice. PWVart, pulse wave 
velocity by Arteriograph; aoSBP, aortic blood pressure; aoAix aortic augmentation index; bpm, beats per 
minute; brAix, brachial augmentation index; CAVI, cardio-ankle vascular index; DBP, diastolic blood 
pressure; HR heart rate; SBP, systolic blood pressure. Values are mean (95% confidence interval) 
